uploads/2018/05/Chart-007-1.jpg

How Analysts View Allergan after Its 1Q18 Earnings

By

Updated

Wall Street analysts’ estimates

Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.

Article continues below advertisement

Analysts’ ratings

Allergan’s stock price has fallen ~39.5% over the last 12 months, and it’s fallen ~9.8% in 2018 year-to-date. Analysts’ estimates show that the stock has a potential to return ~40.5% over the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $207.35 per share, compared to its price of $151.07 per share on May 2.

Analysts’ recommendations

On May 4, 26 analysts were tracking Allergan stock. Of these analysts, five recommended a “strong buy,” 12 recommended a “buy,” and seven recommended a “hold.” None of the analysts recommended a “sell” for Allergan. The consensus rating for Allergan stands at ~2.2, which represents a “strong buy” for momentum and long-term investors.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 1.5% of its total investments in Allergan (AGN), 3.8% in Mylan NV (MYL), 7.3% in AbbVie (ABBV), and 8.1% in Abbott Laboratories (ABT).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Advertisement

More From Market Realist